Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

Lotung Poh-Ai Hospital120 enrolled

Overview

A large dose of PPI is effective in preventing peptic ulcer rebleeding. The investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.

A bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. Endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with bleeding peptic ulcers and is now recommended as the first hemostatic modality for these patients. In the past few years, adjuvant use of a high-dose proton pump inhibitor (PPI) after endoscopic therapy has been endorsed in some studies, two consensus statements and two meta-analysis. In our previous experience, we used omeprazole 160 mg /day infusion instead of 8 mg/h in these patients and obtained a good result . The objectives of this study are to assess the outcomes of two different regimens of high dose of intravenous pantoprazole after endoscopic therapy in patients with peptic ulcer bleeding.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

120

Conditions

Peptic Ulcer Hemorrhage

Interventions

pantoprazoleDRUG

pantoprazole 40 mg/q6h IV infusion for three days

pantoprazoleDRUG

pantoprazole 8 mg/h IV infusion for three days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients were accepted for endoscopic therapy if a peptic ulcer with active bleeding, a non-bleeding visible vessel (NBVV) or an adherent blood clot at the ulcer base was observed within 24 hours of hospital admission. Exclusion Criteria: * If patients were pregnant * Did not obtain initial hemostasis with endoscopic injection of epinephrine * Did not give written informed consent * Had bleeding tendency (platelet count \< 50×109/L, serum prothrombin \< 30% of normal, or were taking anticoagulants), uremia.

Locations (1)

Lotung Poh-Ai hospital

Yilan, Taiwan

Outcomes

Primary Outcomes

The primary end point was recurrent bleeding before discharge and within 14 days.

Time frame: About one year

Secondary Outcomes

At day 14, volume of blood transfused, number of surgeries performed, and the mortality rates of the two groups are compared.

Time frame: about one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.